Prevention of the cryptic epitope SLAYGLR within osteopontin does not influence susceptibility to Candida albicans infection

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 7, 2005, Pages 3053-3055

  Sato, Ikuko ^a   Yamamoto, Nobuchika ^a   Yamazaki, Harumi ^a   Hashimoto, Seiji ^a   Hino, Motohiro ^a   Sakai, Fumihiko ^a   Fujie, Akihiko ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPITOPE; IMMUNOGLOBULIN G; INTERLEUKIN 1; NEUTRALIZING ANTIBODY; OSTEOPONTIN; THROMBIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; KIDNEY; LEUKOCYTE COUNT; MOUSE; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; CANDIDA ALBICANS; CANDIDIASIS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; EPITOPES; FEMALE; HUMANS; KIDNEY; MICE; MICE, INBRED ICR; OSTEOPONTIN; SIALOGLYCOPROTEINS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 21444449356     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.7.3053-3055.2005     Document Type: Article

References (14)

1. Ashkar, S., G. F. Weber, V. Panoutsakopoulou, M. E. Sanchirico, M. Jansson, S. Zawaideh, S. R. Rittling, D. T. Denhardt, M. J. Glimcher, and H. Cantor. 2000. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287:860-864.
2. Carron, C. P., D. M. Meyer, V. W. Engleman, J. G. Rico, P. G. Ruminski, R. L. Ornberg, W. F. Westlin, and G. A. Nickels. 2000. Peptidemimetic antagonists of alphaheta3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, not osteoclast adhesion to bone. J. Endocrinol. 165:587-598.
3. Denning, D. W., L. Hall, M. Jackson, and S. Hollis. 1995. Efficacy of D0870 compared with those of itraconazolc and amphotericin B in two murine models of invasive aspergillosis. Antimicrob. Agents Chemother. 39:1809-1814.
4. Food and Drug Administration. 17 August 2001. Safety update on TNF-α antagonists: infliximab and etanercept. Center for Biologies Evaluation and Research, Food and Drug Administration, Rockville, Md.
5. Ihara, H., D. T. Denhardt, K. Furuya, T. Yamashita, Y. Muguruma, K. Tsuji, K. A. Hruska, K. Higashio, S. Enomoto, A. Nifuji, S. R. Rittling, and M. Noda. 2001. Parathyroid hormone-induced bone resorption does not occur in the absence of osteopontin. J. Biol. Chem. 276:13065-13071.
6. Ikeda, F., Y. Wakai, S. Matsumoto, K. Maki, E. Watabe, S., Tawara, T. Goto, Y. Watanabe, F. Matsumoto, and S. Kuwahara. 2000. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob. Agents Chemother. 44:614-618.
7. Koguchi, Y., K. Kawakami, K. Uezu, K. Fukushima, S. Kon, M. Maeda, A. Nakamoto, I. Owan, M. Kubo, N. Kudeken, M. Azuma, S. Yara, T. Shinzato, F. Higa, M. Tateyama, J. Kadota, H. Mukae, S. Kohno, T. Uede, and A. Saito. 2003. High plasma osteopontin level and its relationship with IL-12-mediated Th1 response in tuberculosis. Am. J. Respir. Crit. Care Med. 15:1355-1359.
8. Kon, S., M. Maeda, T. Segawa, Y. Hagiwara, Y. Horikoshi, S. Chikuma, K. Tanaka, M. M. Rashid, M. Inobe, A. F. Chambers, and T. Uede. 2000. Antibodies to different peptides in osteopontin reveal complexities in the various secreted forms. J. Cell. Biochem. 77:487-498.
9. Nakamura, I., H. Tanaka, G. A. Rodan, and L. T. Duong. 1998. Echistatin inhibits the migration of murine prefusion osteoclasts and the formation of multinucleated osteoclast-like cells. Endocrinology 139:5182-5193.
10. Nau, G. J., G. L. Chupp, J. F. Emile, E. Jouanguy, J. S. Herman, J. L. Casanova, and R. A. Young. 2000. Osteopontin expression correlates with clinical outcome in patients with mycobacterial infection. Am. J. Pathol. 157:37-42.
11. Nau, G. J., L. Liaw, G. L. Chupp, J. S. Berman, B. L. Hogan, and R. A. Young. 1999. Attenuated host resistance against Mycobacterium bovis BCG infection in mice lacking osteopontin. Infect. Immun. 67:4223-4230.
12. Ohshima, S., H. Kobayashi, N. Yamaguchi, K. Nishioka, M. Umeshita-Sasai, T. Mima, S. Nomura, S. Kon, M. Inobe, T. Uede, and Y. Saeki. 2002. Expression of osteopontin at sites of bone erosion in a murine experimental arthritis model of collagen-induced arthritis: possible involvement of osteopontin in bone destruction in arthritis. Arthritis Rheum. 46:1094-1101.
13. Shanahan, J. C., and E. W. S. Clair. 2002. Tumor necrosis factor-α blockade: a novel therapy for rheumatic disease. Clin. Immunol. 103:231-242.
14. Yamamoto, N., F. Sakai, S. Kon, J. Morimoto, C. Kimura, H. Yamazaki, I. Okazaki, N. Seki, T. Fujii, and T. Uede. 2003. Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis. J. Clin. Investig. 112:181-188.